{"id":"W4408851570","doi":"10.1016/j.ygyno.2025.03.018","title":"ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety","year":2025,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Nova (rocket); Oncology; Ovarian cancer; Term (time); Gynecology; Internal medicine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001089751,0.0005886023,0.001499157,0.0002396567,0.0001806227,0.0008876574,0.0004894399,0.000652472,0.00280504],"category_scores_gemma":[0.001104886,0.0001955492,0.001397803,0.0002652192,0.0005287321,0.0008090255,0.0003463751,0.002335166,0.0004572165],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000682932,"about_ca_system_score_gemma":0.0006579006,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000474706,"about_ca_topic_score_gemma":0.002242543,"domain_scores_codex":[0.9996789,0.0001601918,0.00001869867,0.00004147836,0.00003930975,0.00006143624],"domain_scores_gemma":[0.9995764,0.0001024882,0.000104892,0.00004866484,0.00002327095,0.000144328],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5858541,0.005523344,0.01014671,0.002202182,0.004800916,0.0003455433,0.0002014854,0.005508835,0.01347954,0.001406182,0.006342405,0.3641887],"study_design_scores_gemma":[0.5790142,0.2943775,0.07150508,0.000670888,0.005060187,0.001654793,0.0003231413,0.007752954,0.008297514,0.003563445,0.02761552,0.0001648108],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9765519,0.01547416,0.0005601971,0.001061231,0.0002848637,0.0003150184,0.001456976,0.00007178781,0.004223854],"genre_scores_gemma":[0.9829312,0.006026905,0.000768428,0.001083799,0.0001656436,0.0003012224,0.002489953,0.00003431249,0.006198503],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00280504,"threshold_uncertainty_score":0.009383857,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06785633356941483,"score_gpt":0.4083588731869353,"score_spread":0.3405025396175204,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}